Richard D Ronca1, Alyssa M Myers2, Doina Ganea3, Ronald F Tuma1, Ellen A Walker2, Sara Jane Ward4. 1. Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA. 2. Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140, USA. 3. Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140, USA. 4. Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA. Electronic address: saraward@temple.edu.
Abstract
AIMS: We have recently demonstrated that treatment with a cannabinoid CB2 agonist was protective in a mouse middle cerebral artery occlusion model of cerebral ischemia/reperfusion injury. The present study aimed to determine whether these protective effects of CB2 agonism would extend to a mouse photoinjury model of permanent ischemia and determine associated alterations in cognition and infarct size. MAIN METHODS: Mice received three injections of the CB2 selective agonist O-1966 or vehicle 1h prior to and 2 and 5days following induction of stroke. Infarct size was assessed at 1, 3, or 7days post-injury and learning and memory effects of injury and O-1966 treatment were assessed on days 6 and 7 using a novel object recognition task and an operant acquisition and retention procedure. KEY FINDINGS: O-1966 treated mice had significantly smaller infarct volumes compared with vehicle treated mice. Photoinjury was also associated with a significant memory impairment on day 7 post-injury, and this deficit was reversed with O-1966 treatment. Surprisingly, sham-operated mice receiving O-1966 treatment showed a significant learning deficit in both the recognition and operant tasks compared with vehicle treated sham mice. SIGNIFICANCE: We conclude that CB2 activation is protective against cognitive deficits and tissue damage following permanent ischemia, but may dysregulate glial or neuronal function of learning and memory circuits in the absence of injury and/or inflammation.
AIMS: We have recently demonstrated that treatment with a cannabinoidCB2 agonist was protective in a mousemiddle cerebral artery occlusion model of cerebral ischemia/reperfusion injury. The present study aimed to determine whether these protective effects of CB2 agonism would extend to a mouse photoinjury model of permanent ischemia and determine associated alterations in cognition and infarct size. MAIN METHODS:Mice received three injections of the CB2 selective agonist O-1966 or vehicle 1h prior to and 2 and 5days following induction of stroke. Infarct size was assessed at 1, 3, or 7days post-injury and learning and memory effects of injury and O-1966 treatment were assessed on days 6 and 7 using a novel object recognition task and an operant acquisition and retention procedure. KEY FINDINGS:O-1966 treated mice had significantly smaller infarct volumes compared with vehicle treated mice. Photoinjury was also associated with a significant memory impairment on day 7 post-injury, and this deficit was reversed with O-1966 treatment. Surprisingly, sham-operated mice receiving O-1966 treatment showed a significant learning deficit in both the recognition and operant tasks compared with vehicle treated sham mice. SIGNIFICANCE: We conclude that CB2 activation is protective against cognitive deficits and tissue damage following permanent ischemia, but may dysregulate glial or neuronal function of learning and memory circuits in the absence of injury and/or inflammation.
Authors: Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma Journal: Transl Stroke Res Date: 2012-07-26 Impact factor: 6.829
Authors: Ruiqing Ni; Adrienne Müller Herde; Ahmed Haider; Claudia Keller; Georgios Louloudis; Markus Vaas; Roger Schibli; Simon M Ametamey; Jan Klohs; Linjing Mu Journal: Mol Imaging Biol Date: 2021-10-12 Impact factor: 3.484
Authors: Daniel Silva-Peña; Patricia Rivera; Francisco Alén; Antonio Vargas; Leticia Rubio; Nuria García-Marchena; Francisco Javier Pavón; Antonia Serrano; Fernando Rodríguez de Fonseca; Juan Suárez Journal: Front Mol Neurosci Date: 2019-04-24 Impact factor: 5.639